Journal: Cells

Article Title: RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer.

doi: 10.3390/cells12030444

Figure Lengend Snippet: Figure 6. Reduction of RUNX1 transcriptional activity enhances enzalutamide and paclitaxel treat- ment in CSC-like cells. MDA-MB-453 cells were cultured for 72 h in forced-suspension and treated with either 10 nM Px, 40 µM Enza and 2 µM AI-10-104 (A)/0.5 µM AI-10-49 (B) or the doses used for attached conditions (dark gray bar): 2 nM Px, 20 µM Enza and 1 µM AI-10-104 (A)/0.25 µM AI-10-49 (B) for 72 h. Cell viability was determined by MTT and the results are expressed as the relative absorbance (570 nm) to control treatment (DMSO, 1.00). Statistical differences are shown for the combination of the 3 drugs (black bar) vs. the rest of the treatments (gray bars) or vehicle (white bar). For more details see Suppl Table S3. One-way ANOVA with Tukey multiple comparison was performed from three independent experiments, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: Dihydrotestosterone (DHT, Sigma-Aldrich) was diluted in ethanol, enzalutamide (Enza, Sigma-Aldrich; #PHB00235) in DMSO, Paclitaxel (Px, Cell Signaling Technology, Danvers, MA, USA; #98075) in DMSO and RUNX1 inhibitors AI-10-104 (Glixx Laboratories, Hopkinton, MA, USA; GLXC-20705) and AI-10-49 (Glixx Laboratories GLXC-07203) in DMSO.

Techniques: Activity Assay, Cell Culture, Suspension, Control, Comparison